CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant ...
Reneo Pharmaceuticals, developing therapies for rare genetic mitochondrial diseases, has been added to the Russell 3000 index and raised around $55 million through a recent public offering. RPHM's ...
Researchers from Guandong Pharmaceutical University reported on the synthesis and preclinical characterization of a series of novel long-acting peroxisome proliferator-activated receptor (PPAR) ...
Seladelpar, an investigational selective agonist of peroxisome proliferator–activated receptor-delta (PPAR-δ), significantly improves liver biomarkers of disease activity and bothersome symptoms of ...
The FDA granted accelerated approval to oral elafibranor (Iqirvo) for treating primary biliary cholangitis (PBC) in adults, drugmaker Ipsen announced on Monday. A first-in-class dual peroxisome ...
T3D-959, an oral dual delta/gamma peroxisome proliferator-activated nuclear receptor (PPAR) agonist, has shown promise in a phase 2 randomized, placebo-controlled study of adults with mild-to-moderate ...
In this new article publication from Acta Pharmaceutica Sinica B, authors Youbo Zhang, Tingting Yan, Tianxia Wang and colleagues from Peking University, Beijing, China, National Institutes of Health, ...
The MarketWatch News Department was not involved in the creation of this content. Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback